Meeting
2022 ASCO Annual Meeting
Safety and efficacy of daratumumab use in patients with renal impairment and hemodialysis.
Authors
Mateusz Niewinski
NYU Langone Health - Long Island, Mineola, NY
Mateusz Niewinski , Jamie Chin-Hon , Meredith Akerman , Faith Davies , Gareth Morgan , Marc Justin Braunstein
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 8026)
DOI
10.1200/JCO.2022.40.16_suppl.8026
Abstract #
8026
Poster Bd #
450
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
OMNIA-2: Phase I/II study of ANV419, an IL-2R-βγ targeted antibody-IL-2 fusion protein, in patients with relapsed or refractory multiple myeloma.
First Author: Dagmar Hess
Poster
2024 ASCO Annual Meeting
Unveiling consistency: A large-scale analysis of conference proceedings and subsequent publications in oncology clinical trials using large language models.
First Author: Kyeryoung Lee
Poster
2023 ASCO Annual Meeting
MagnetisMM-6: An open-label, multicenter, randomized phase 3 study of elranatamab + daratumumab + lenalidomide (EDR) versus daratumumab + lenalidomide + dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM).
First Author: Sebastian Grosicki
Poster
2023 ASCO Annual Meeting
EXCALIBER-RRMM: A phase 3, two-stage study of iberdomide, daratumumab, and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
First Author: Sagar Lonial